Slammed by FDA re­jec­tion, Aque­s­tive vows to re­file by end of year

Aque­s­tive Ther­a­peu­tics is still reel­ing from a pre­cip­i­tous drop in its stock price af­ter the FDA re­ject­ed its oral film for seizure con­trol.

Liber­vant, a buc­cal film for­mu­la­tion of the gener­ic drug di­azepam, would have been the biotech’s sec­ond com­mer­cial treat­ment for epilep­sy fol­low­ing Sym­pa­zan (clobazam), which is ap­proved specif­i­cal­ly for Lennox-Gas­taut syn­drome.

Ac­cord­ing to a re­lease out Fri­day, reg­u­la­tors are main­ly wor­ried about phar­ma­co­ki­net­ics, cit­ing in the com­plete re­sponse let­ter a study where “cer­tain weight groups showed a low­er drug ex­po­sure lev­el than de­sired.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER